Verrica Pharmaceuticals (VRCA) PT Lowered to $18 at Needham & Company on Financing Overhang, Analyst Notes "Attractive Sales Potential" of Ycanth
Tweet Send to a Friend
Needham & Company analyst Serge Belanger lowered the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $18.00 (from $20.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
